Matches in SemOpenAlex for { <https://semopenalex.org/work/W2766826981> ?p ?o ?g. }
- W2766826981 endingPage "51" @default.
- W2766826981 startingPage "41" @default.
- W2766826981 abstract "Marizomib (MRZ) is an irreversible, pan-subunit proteasome inhibitor (PI) in clinical development for relapsed/refractory multiple myeloma (RRMM) and glioma. This study analysed MRZ, pomalidomide (POM) and low-dose dexamethasone (Lo-DEX) [PMD] in RRMM to evaluate safety and determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D). Intravenous MRZ (0·3-0·5 mg/m2 ) was administered over 2 h on days 1, 4, 8, 11; POM (3-4 mg) on days 1-21; and Lo-DEX (5 or 10 mg) on days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 22 and 23 of every 28-day cycle. Thirty-eight patients were enrolled that had received a median of 4 (range 1-10) prior lines of therapy; all patients received prior lenalidomide and bortezomib. No dose-limiting toxicities (DLTs) were observed and 0·5 mg/m2 MRZ was determined to be the RP2D. The most common treatment-related ≥Grade 3 adverse events were: neutropenia (11/38 patients: 29%), pneumonia (4/38 patients 11%), anaemia (4/38 patients; 11%) and thrombocytopenia (4/38 patients; 11%). The overall response rate and clinical benefit rate was 53% (19/36) and 64% (23/36), respectively. In conclusion, PMD was well tolerated and demonstrated promising activity in heavily pre-treated, high-risk RRMM patients." @default.
- W2766826981 created "2017-11-10" @default.
- W2766826981 creator A5002073335 @default.
- W2766826981 creator A5006765393 @default.
- W2766826981 creator A5018838899 @default.
- W2766826981 creator A5034791164 @default.
- W2766826981 creator A5041318626 @default.
- W2766826981 creator A5043526996 @default.
- W2766826981 creator A5049711954 @default.
- W2766826981 creator A5054269070 @default.
- W2766826981 creator A5063334369 @default.
- W2766826981 creator A5064710410 @default.
- W2766826981 creator A5066469501 @default.
- W2766826981 creator A5071712855 @default.
- W2766826981 creator A5087542189 @default.
- W2766826981 creator A5088292582 @default.
- W2766826981 date "2017-10-26" @default.
- W2766826981 modified "2023-10-14" @default.
- W2766826981 title "A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results" @default.
- W2766826981 cites W1540671296 @default.
- W2766826981 cites W1898969431 @default.
- W2766826981 cites W1902692042 @default.
- W2766826981 cites W1969648097 @default.
- W2766826981 cites W1975305152 @default.
- W2766826981 cites W1975916512 @default.
- W2766826981 cites W1985864219 @default.
- W2766826981 cites W1987583882 @default.
- W2766826981 cites W1999964913 @default.
- W2766826981 cites W2001786657 @default.
- W2766826981 cites W2003734726 @default.
- W2766826981 cites W2007644267 @default.
- W2766826981 cites W2010184965 @default.
- W2766826981 cites W2033944464 @default.
- W2766826981 cites W2056181814 @default.
- W2766826981 cites W2069992059 @default.
- W2766826981 cites W2087228127 @default.
- W2766826981 cites W2091773528 @default.
- W2766826981 cites W2115219209 @default.
- W2766826981 cites W2118820477 @default.
- W2766826981 cites W2123159083 @default.
- W2766826981 cites W2131491521 @default.
- W2766826981 cites W2132485651 @default.
- W2766826981 cites W2136541422 @default.
- W2766826981 cites W2145412346 @default.
- W2766826981 cites W2145493193 @default.
- W2766826981 cites W2162468902 @default.
- W2766826981 cites W2166526813 @default.
- W2766826981 cites W2236313888 @default.
- W2766826981 cites W2261920671 @default.
- W2766826981 cites W2302708051 @default.
- W2766826981 cites W2316542938 @default.
- W2766826981 cites W2343386476 @default.
- W2766826981 cites W2344865582 @default.
- W2766826981 cites W2346753659 @default.
- W2766826981 cites W2604179432 @default.
- W2766826981 cites W2606120108 @default.
- W2766826981 cites W2890318115 @default.
- W2766826981 cites W4254421610 @default.
- W2766826981 doi "https://doi.org/10.1111/bjh.14987" @default.
- W2766826981 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6860364" @default.
- W2766826981 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29076150" @default.
- W2766826981 hasPublicationYear "2017" @default.
- W2766826981 type Work @default.
- W2766826981 sameAs 2766826981 @default.
- W2766826981 citedByCount "57" @default.
- W2766826981 countsByYear W27668269812018 @default.
- W2766826981 countsByYear W27668269812019 @default.
- W2766826981 countsByYear W27668269812020 @default.
- W2766826981 countsByYear W27668269812021 @default.
- W2766826981 countsByYear W27668269812022 @default.
- W2766826981 countsByYear W27668269812023 @default.
- W2766826981 crossrefType "journal-article" @default.
- W2766826981 hasAuthorship W2766826981A5002073335 @default.
- W2766826981 hasAuthorship W2766826981A5006765393 @default.
- W2766826981 hasAuthorship W2766826981A5018838899 @default.
- W2766826981 hasAuthorship W2766826981A5034791164 @default.
- W2766826981 hasAuthorship W2766826981A5041318626 @default.
- W2766826981 hasAuthorship W2766826981A5043526996 @default.
- W2766826981 hasAuthorship W2766826981A5049711954 @default.
- W2766826981 hasAuthorship W2766826981A5054269070 @default.
- W2766826981 hasAuthorship W2766826981A5063334369 @default.
- W2766826981 hasAuthorship W2766826981A5064710410 @default.
- W2766826981 hasAuthorship W2766826981A5066469501 @default.
- W2766826981 hasAuthorship W2766826981A5071712855 @default.
- W2766826981 hasAuthorship W2766826981A5087542189 @default.
- W2766826981 hasAuthorship W2766826981A5088292582 @default.
- W2766826981 hasBestOaLocation W27668269811 @default.
- W2766826981 hasConcept C121332964 @default.
- W2766826981 hasConcept C126322002 @default.
- W2766826981 hasConcept C142424586 @default.
- W2766826981 hasConcept C197934379 @default.
- W2766826981 hasConcept C2776063141 @default.
- W2766826981 hasConcept C2776364478 @default.
- W2766826981 hasConcept C2777063308 @default.
- W2766826981 hasConcept C2777478702 @default.
- W2766826981 hasConcept C2778524551 @default.
- W2766826981 hasConcept C2778850193 @default.
- W2766826981 hasConcept C2780401358 @default.